CorMedix (AMEX: CRMD) announced that it received a Special Protocol Assessment approval letter from the FDA on the design of a pivotal Phase 3 trial for Deferiprone. Deferiprone is indicated for Contrast-Induced Acute Kidney Injury. The “SPA” takes into consideration a modification to the dosing regimen contained in the previously submitted protocol.